The opportunity for greater patient and public involvement and engagement in drug development and regulation
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Rent or buy this article
Get just this article for as long as you need it
Prices may be subject to local taxes which are calculated during checkout
Nature Reviews Drug Discovery 22, 337-338 (2023)
O.L.A. receives funding from the National Institute for Health and Care Research (NIHR) Birmingham Biomedical Research Centre (BRC), the NIHR Applied Research Collaboration (ARC), NIHR Birmingham-Oxford Blood and Transplant Research Unit (BTRU) in Precision Transplant and Cellular Therapeutics, at the University of Birmingham and University Hospitals Birmingham NHS Foundation, Innovate UK (part of UK Research and Innovation), Gilead Sciences, Merck and Sarcoma UK. S.C.R. receives funding from Merck, UK SPINE, and European Regional Development Fund – Demand Hub. M.J.C. receives funding from NIHR BRC, NIHR BTRU, the NIHR Surgical Reconstruction and Microbiology Research Centre and NIHR ARC West Midlands, UK SPINE, European Regional Development Fund – Demand Hub, Health Data Research UK at the University of Birmingham and University Hospitals Birmingham NHS Foundation Trust, Innovate UK (part of UK Research and Innovation), Macmillan Cancer Support, UCB Pharma, GSK, and Gilead Sciences. The views expressed in this article are the personal views of the authors and may not be understood or quoted as being made on behalf of or reflecting the position of the regulatory agencies or organizations with which the authors are employed/affiliated.
Aiyegbusi, O. L. et al. Patient and public perspectives on cell and gene therapies: a systematic review. Nat. Commun. 11, 6265 (2020).
Beauchamp, T. L. & Childress, J. F. Principles of Biomedical Ethics (Oxford Univ. Press, 2001).
Turner, G., Aiyegbusi, O. L., Price, G. Skrybant, M. & Calvert, M. Moving beyond project-specific patient and public involvement in research. J. R. Soc. Med. 113, 16–23 (2020).
Calvert, M. J. et al. Advancing UK regulatory science and innovation in healthcare. J. R. Soc. Med. 114, 5–11 (2021).
O.L.A. declares personal fees from Gilead Sciences, Merck and GSK outside the submitted work. S.C.R. declares personal fees from Merck. M.J.C. received personal fees from Astellas, Aparito, CIS Oncology, Takeda, Merck, Daiichi Sankyo, Glaukos, GSK and the Patient-Centered Outcomes Research Institute outside the submitted work. In addition, a family member of M.J.C. owns shares in GSK. All other authors declare no competing interests.